Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
Elvira Pelosi, Germana Castelli, Ugo Testa
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2718-2718
Open Access | Times Cited: 22

Showing 22 citing articles:

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Antonio Tapia‐Galisteo, Luís Álvarez-Vallina, Laura Sanz
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 55
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
Michael Wysota, Marina Konopleva, Shane Mitchell
Current Oncology Reports (2024) Vol. 26, Iss. 4, pp. 409-420
Open Access | Times Cited: 12
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement
Mingxia Jiang, Qiao Li, Binghe Xu
Drug Resistance Updates (2024) Vol. 75, pp. 101086-101086
Closed Access | Times Cited: 8
Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations
Beatriz Guijarro-Albaladejo, Cristina Marrero-Cepeda, Eduardo Rodríguez‐Arbolí, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 5
Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm
Domenico Galati, Serena Zanotta, Francesca Florio, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2732-2732
Open Access
Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)
Frances M. Cole, George S. Laszlo, Margaret C. Lunn-Halbert, et al.
Leukemia (2025)
Closed Access
Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123
Serena Zanotta, Domenico Galati
(2024)
Open Access | Times Cited: 4
Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123
Serena Zanotta, Domenico Galati, Rosaria De Filippi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1454-1454
Open Access | Times Cited: 2
Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia
Elżbieta Bartoszewska, Maciej Tota, Monika Kisielewska, et al.
Cells (2024) Vol. 13, Iss. 18, pp. 1596-1596
Open Access | Times Cited: 2
Construction of an immune-related prognostic signature and lncRNA–miRNA–mRNA ceRNA network in acute myeloid leukemia
Ling Qin, Boya Li, Shijie Wang, et al.
Journal of Leukocyte Biology (2024) Vol. 116, Iss. 1, pp. 146-165
Open Access | Times Cited: 1
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies
Pasquale Niscola, Valentina Gianfelici, Gianfranco Catalano, et al.
Current Oncology (2024) Vol. 31, Iss. 11, pp. 6632-6658
Open Access | Times Cited: 1
The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions
Ri Han Wu, Chen Zhu, Pei Han Yu, et al.
Toxicology and Applied Pharmacology (2023) Vol. 473, pp. 116585-116585
Closed Access | Times Cited: 4
Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview
Gerardo Cazzato, Marialessandra Capuzzolo, Emilio Bellitti, et al.
Hematology Reports (2023) Vol. 15, Iss. 4, pp. 696-706
Open Access | Times Cited: 3
Dendritic Cell Subpopulations Are Associated with Prognostic Characteristics of Breast Cancer after Neoadjuvant Chemotherapy—An Observational Study
Agnieszka Łazarczyk, Joanna Streb, Anna Glajcar, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15817-15817
Open Access | Times Cited: 2
Tumeur à cellules dendritiques plasmocytoïdes blastiques
G. Jeudy, S. Dalac‐Rat, B. Bonniaud, et al.
Annales de Dermatologie et de Vénéréologie - FMC (2024) Vol. 4, Iss. 4, pp. 270-273
Closed Access
Membrane Antigen Targeting in Acute Myeloid Leukemia Using Antibodies or CAR-T Cells
Ugo Testa, Germana Castelli, Elvira Pelosi
Cancers (2024) Vol. 16, Iss. 21, pp. 3627-3627
Open Access
Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities
Milica Vukotić, Sunčica Kapor, Felipe Simón, et al.
Heliyon (2024) Vol. 10, Iss. 3, pp. e25081-e25081
Open Access
Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia
Christos Stafylidis, Dimitra Vlachopoulou, Christina‐Nefeli Kontandreopoulou, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 1082-1082
Open Access
Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted Treatments
Pasquale Niscola, Nélida I. Noguera, Valentina Gianfelici, et al.
(2024)
Open Access
Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies
Xiaohuan Peng, Futian Tang, Yanhong Li, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA
Ugo Testa, Germana Castelli, Elvira Pelosi
Mediterranean Journal of Hematology and Infectious Diseases (2023) Vol. 15, Iss. 1, pp. e2023038-e2023038
Open Access | Times Cited: 1
Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia
Christos Stafylidis, Dimitra Vlachopoulou, Christina‐Nefeli Kontandreopoulou, et al.
(2023)
Open Access | Times Cited: 1
Page 1

Scroll to top